BioSpace News Archive

BioCryst Pharmaceuticals, Inc. announced that the Canadian Agency for Drugs and Technologies in Health Canadian Drug Expert Committee has issued a positive recommendation for ORLADEYO® to be reimbursed for the routine prevention of attacks of hereditary angioedema in adults and pediatric patients 12 years of age and older.

MDxHealth SA, a commercial-stage precision diagnostics company, announced its financial results for the fourth quarter and year ended December 31, 2022, and provided a business update and outlook for 2023.

Neurona Therapeutics, a clinical-stage biotherapeutics company advancing regenerative cell therapies for the treatment of neurological disorders, announced that Cory R. Nicholas, Ph.D., Neurona’s chief executive officer, will provide a corporate update at the Oppenheimer 33rd Annual Healthcare Conference on Wednesday, March 15 at 2:00 pm ET.

Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that Phil Pang, M.D., Ph.D., Executive Vice President, Chief Medical Officer and Interim Head of Research, is scheduled to present at the Barclays Global Healthcare Conference on Wednesday, March 15, at 7:15 a.m. PT / 10:15 a.m. ET.

Clene Inc. and its wholly owned subsidiary Clene Nanomedicine, Inc., a clinical-stage biopharmaceutical company focused on revolutionizing the treatment of neurodegenerative diseases, announced that it will host a live audio webcast at 7:30 a.m. ET tomorrow, Thursday, March 9, to review new clinical results from the CNM-Au8® arm of the Healey ALS Platform Trial.

Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today reported financial results for the fourth quarter and year-end 2022 and provided a business update.

Estrella Biopharma, Inc. today announced that the U.S. Food and Drug Administration (“FDA”) has cleared Estrella’s Investigational New Drug (“IND”) application for Estrella’s lead product candidate, EB103.

Molecure S.A. (“Molecure”: WSE: MOC) announces today that the first patient has been dosed in a Phase I trial evaluating OATD-02 as a monotherapy in cancer patients with advanced solid tumors.

Infusion Associates (IA), one of the Midwest’s leading providers of medically prescribed outpatient infusion and injection therapies, completed their first Briumvi™ (ublituximab-xiiy) infusion treatment for a patient at their Plymouth, Minnesota location.

AiM Medical Robotics, a developer of MRI-compatible intraoperative robotics for neurosurgery and other applications, announced changes to its executive team.